Application of liquid biopsy based on CTC and ctDNA in postoperative monitoring of high-risk non-muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066347

Enrollment

Unknown

Registered

2022-12-01

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Gold Standard:Pathological testing

Index test:Cell counting, DNA extraction, PCR, Gene testing

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Male or female = 18 years old; (2) Non-muscle-invasive urothelial carcinoma of the bladder (NMIBC); (3) The pathological features were T1 and high grade; (4) It was accompanied by one of the following conditions: multiple, recurrence, > 3 cm, carcinoma in situ (CIS), vascular tumor thrombus, and adverse pathological type.

Exclusion criteria

Exclusion criteria: (1) Self-report of pregnancy; (2) The patient may not comply with the requirements of the study (e.g., cannot comply with the requirements of this clinical study due to his/her health condition or because he/she is participating in another study); (3) Current or previous history of other tumors.

Design outcomes

Primary

Measure	Time frame
Circulating tumor cell count;	—

Countries

China

Contacts

Public ContactLei Wang

Peking University Shougang Hospital

wanglei_09243633@163.com15101184209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026